---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-035657"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-09-04T10:01:59+00:00"
generated_at: "2026-09-04T10:05:03.504189+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Ionis' ZANVASTRO (zilganersen) for Alexander disease

## Summary
- ZANVASTRO is first and only disease-modifying treatment for AxD; 50 mg intrathecal quarterly.
- Pivotal study met primary endpoint: gait speed stabilization at Week 61 (LS mean diff 33.3%, p=0.041).
- FDA granted Rare Pediatric Disease Priority Review Voucher with approval.
- Recordati holds ex-U.S. rights; EU/Japan regulatory submissions expected in 2027.
- ZANVASTRO available in U.S. in coming weeks; Ionis' first independent neurology launch.

## SEC filing metadata
- accession: 0001140361-26-035657
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-09-04T10:01:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/0001140361-26-035657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126035657/ef20081649_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-035657
- JSON: https://secwatch.observer/filing/0001140361-26-035657.json
- Plain text: https://secwatch.observer/filing/0001140361-26-035657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.